logo

Stock Screener

Forex Screener

Crypto Screener

CRDF

Cardiff Oncology, Inc. (CRDF)

$

3.94

+0.29 (7.36%)


Key metrics

Financial statements

Free cash flow per share

Free cash flow per share

-0.6426

Market cap

Market cap

262.1 Million

Price to sales ratio

Price to sales ratio

547.2068

Debt to equity

Debt to equity

0.0191

Current ratio

Current ratio

6.2231

Income quality

Income quality

0.8750

Average inventory

Average inventory

0

ROE

ROE

-0.7646



Technology

Technology

Technology – consumer electronics

Largecap

Largecap

With a market cap of 121,78 bil stock is ranked 1

Low risk

Low risk

ISS score of this stock is ranked 1


Company description

Profile

Cardiff Oncology, Inc. is a clinical-stage oncology company based in San Diego, California, specializing in the development of novel cancer treatments for patients. The company's lead drug candidate, onvansertib, is an oral selective Polo-like Kinase 1 Inhibitor designed for anti-cancer therapeutics. In addition to onvansertib, Cardiff Oncology is advancing CY140, which inhibits PLK1, PLK2, and PLK3, currently in phase 1/2 studies for solid tumors and leukemias. The company is actively conducting clinical trials for metastatic colorectal cancer and has another promising candidate, TROV-054, which is in Phase 1b/2 studies combined with FOLFIRI and bevacizumab. Furthermore, Cardiff Oncology's TROV-053 is in Phase II clinical trials in conjunction with Zytiga for metastatic castration-resistant prostate cancer. The diluted EPS is -$0.95 accounting for potential share dilution. The company incurred an interest expense of $0.00 reflecting its debt servicing obligations. The operating income ratio is -71.23 indicating the company's operational profitability margin. Moreover, the net total of other income and expenses is $3,220,000.00 reflecting non-core financial activities. Finally, the EBITDA ratio is -70.64 highlighting the company's operational efficiency. The stock of Cardiff Oncology, Inc. is currently affordable at $3.94 making it suitable for budget-conscious investors. With a high average trading volume of 1,192,833.00 the stock indicates strong liquidity, which is essential for active traders. The company, with a market capitalization of $262,112,042.00 is classified as a small-cap player in the biotechnology space. It is a key player in the oncology industry, contributing significantly to the overall market landscape with its innovative approaches. Furthermore, Cardiff Oncology belongs to the Healthcare sector, driving innovation and growth. This combination of affordability, liquidity, and a strong market position makes Cardiff Oncology an intriguing option for investors looking to engage with a firm that is actively working towards impactful cancer treatments.

What is Cardiff Oncology, Inc. (CRDF)'s current stock price?

The current stock price of Cardiff Oncology, Inc. (CRDF) is $3.94 as of 2025-07-08. Prices may fluctuate during the trading day. For real-time updates, check your brokerage platform or financial news websites.

Investing in Cardiff Oncology, Inc. (CRDF) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.

Analysts predict Cardiff Oncology, Inc. stock to fluctuate between $2.01 (low) and $5.64 (high) in the next 365 days, reflecting market expectations and potential volatility.

As of 2025-07-08, Cardiff Oncology, Inc.'s market cap is $262,112,042, based on 66,525,899 outstanding shares.

Compared to Meta Platforms, Inc. Class A Common Stock, Cardiff Oncology, Inc. has a Lower Market-Cap, indicating a difference in performance.

To buy Cardiff Oncology, Inc. (CRDF) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CRDF. Place an order (Market, Limit, etc.).

The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.

Cardiff Oncology, Inc.'s last stock split was 1:6 on 2019-02-20.

Revenue: $683,000 | EPS: -$0.95 | Growth: 2.15%.

Visit https://www.cardiffoncology.com/investor-relations for detailed financial reports.

You can explore historical data from here

All-time high: $14.98 (2021-02-11) | All-time low: $0.94 (2023-11-10).

Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.


News

CRDF

seekingalpha.com

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Cardiff Oncology's recent trial data readout delay has unnerved the market, but I see this as a potential buying opportunity for speculative investors. Leadership change is not a major risk factor. The new CMO's pedigree suggests confidence in the company's prospects ahead of the catalyst. The delay could suggest an attempt to improve poor data, or an ability to add to already strong data by waiting for more patient second scans.

CRDF

marketwatch.com

Cardiff Oncology Names Roger Sidhu as Medical Chief

Sidhu joined Cardiff from Treadwell Therapeutics, where he was medical chief and acting chief executive officer. Previously, Sidhu spent nearly 10 years at Amgen.

CRDF

globenewswire.com

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development –

CRDF

zacks.com

Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know

Cardiff Oncology (CRDF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CRDF

seekingalpha.com

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

Cardiff Oncology's onvansertib shows promising early results in improving response rates for RAS-mutated colorectal cancer, with a critical data update expected by mid-2025. Financially, CRDF has sufficient funds to operate until early 2027 but will face funding challenges by 2026, potentially impacting stock value. The success of onvansertib in first-line metastatic colorectal cancer is crucial, with high upside potential but significant risk if upcoming data disappoints.

CRDF

zacks.com

Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy?

Cardiff Oncology (CRDF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRDF

zacks.com

All You Need to Know About Cardiff Oncology (CRDF) Rating Upgrade to Buy

Cardiff Oncology (CRDF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CRDF

seekingalpha.com

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Officer Conference Call Participants Joe Catanzaro - Piper Sandler Andy Hsieh - William Blair Robert Burns - H.C. Wainwright Albert Lowe - Craig-Hallum Operator Welcome to the Cardiff Oncology Fourth Quarter 2024 Financial Results and Business Update Conference Call.

CRDF

zacks.com

Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.21 per share a year ago.

CRDF

seekingalpha.com

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II results indicate superior efficacy in first-line treatment, supporting Cardiff's financial stability and long-term investment potential. The competitive landscape includes therapies like LUMAKRAS and KRAZATI, but Onvansertib's mutation-agnostic approach offers a unique advantage.

See all news

logo
Stocks, Indicators, Pattern screeners all at one place
Stock Screener
Forex Screener
Crypto Screener